Literature DB >> 2072742

Clinical and prognostic implications of chromosome 5q deletions: 96 high resolution studied patients.

B Pedersen1, I M Jensen.   

Abstract

Interstitial deletions of the long arm of chromosome 5 (5q-) is the most common structural rearrangement in acute nonlymphocytic leukemia and myelodysplastic syndromes. Owing to the variability of both breakpoints a large number of different deletions occur. However, as banding problems have hitherto precluded the precise localization of the breakpoints, it is still uncertain whether or not different deletions are associated with clinical differences. In this paper relationships between cytogenetic and clinical data were analyzed in 96 5q- cases investigated with high resolution techniques, which allow more precise breakpoint localizations. Twenty-nine cases have not been published before; the others were extracted from the literature. The analyses show: (1) With higher age at diagnosis the proximal breakpoint approaches the centromere. (2) The female patients are older, develop additional chromosome aberrations less often, and tend to live longer than the male patients. (3) del(5)(qI3q33), which is more frequent than any other deletion, tends to be associated with female sex and older age, and shows lower frequencies of additional chromosome abnormalities, and longer survival than the other deletions. It seems to constitute a more benign subgroup than the other deletions. (4) 5q31 is missing in 91 of 93 informative cases and is the most common deleted segment. (5) These results suggest that the deletion of 5q31 may be central in the pathogenesis of 5q- related disorders and that the deletion of other bands has important consequences for prognosis.

Entities:  

Mesh:

Year:  1991        PMID: 2072742

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  2 in total

Review 1.  Chromosome and molecular abnormalities in myelodysplastic syndromes.

Authors:  Pierre Fenaux
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

2.  Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies.

Authors:  Lionel Ades; Thomas Prebet; Aspasia Stamatoullas; Christian Recher; Romain Guieze; Emmanuel Raffoux; Krimo Bouabdallah; Mathilde Hunault; Eric Wattel; Laure Stalnikiewicz; Andrea Toma; Hervé Dombret; Norbert Vey; Marie Sebert; Claude Gardin; Cendrine Chaffaut; Sylvie Chevret; Pierre Fenaux
Journal:  Haematologica       Date:  2016-12-29       Impact factor: 9.941

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.